Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-CLS-7262 · 3 trials · 1 indication
Area under the Curve (AUC)
Area under the Curve (AUC)
To evaluate the effect of ABBV-CLS-7262 on the QTc interval in healthy adult subjects.
Maximum Plasma Concentration \[Cmax\]; Area under the Curve (AUC)
Maximum Plasma Concentration \[Cmax\]; Area under the Curve (AUC)
| Arm | Type | Description |
|---|---|---|
| ABBV-CLS-7262 | EXPERIMENTAL | ABBV-CLS-7262 + Digoxin + Rosuvastatin |
| Sequence 1 | EXPERIMENTAL | Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet |
| Sequence 2 | EXPERIMENTAL | Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet |
| Sequence 3 | EXPERIMENTAL | Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet |
| Sequence 4 | EXPERIMENTAL | Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet |
| Period 1, 2 and 3 ABBV-CLS-7262 | EXPERIMENTAL | * Participants will receive ABBV-CLS-7262 administered under fasted conditions. * Participants will receive ABBV-CLS-7262 administered under fed conditions (high-fat/high-calorie breakfast). * Participants will receive ABBV-CLS-7262 administered with applesauce. |
| Name | Type | Description |
|---|---|---|
| ABBV-CLS-7262 | DRUG | Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin |
| Placebo | DRUG | • single oral dose |
| Moxifloxacin 400mg | DRUG | • single oral dose |
Inclusion Criteria: * Adult volunteers in general good health * Must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures * Individuals between 18 and ...
ABBV-CLS-7262 is an investigational small molecule being developed by AbbVie Inc. (ABBV). It is currently in Phase 1 clinical development, with studies conducted in healthy volunteers. The drug is being evaluated in early-stage trials to assess its safety, tolerability, and pharmacokinetics.
ABBV-CLS-7262 is being studied in healthy volunteers as part of Phase 1 clinical trials. These studies are designed to evaluate the drug's safety, tolerability, and how it is processed by the body. The specific therapeutic indication has not been disclosed in the available trial information.
ABBV-CLS-7262 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. AbbVie is conducting Phase 1 clinical trials of this investigational small molecule in healthy subjects.
ABBV-CLS-7262 is in Phase 1 clinical development. All three completed trials for this drug were Phase 1 studies conducted in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
ABBV-CLS-7262 has been studied in three completed Phase 1 trials: NCT05763459, a drug interaction study with rosuvastatin and digoxin; NCT06145607, a food effect study; and NCT06310876, a thorough QT study. All trials enrolled healthy adults in the United States.
ABBV-CLS-7262 is the code name used by AbbVie for this investigational compound. No alternative names have been disclosed in the available clinical trial information. The drug is identified solely by this designation in the registered trials.